Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib

Mise à jour : Il y a 4 ans
Référence : NCT00320190

Femme et Homme

Extrait

The purpose of this study is to compare the efficacy of dasatinib with that of high-dose (800-mg) imatinib in participants with chronic phase chronic myeloid leukemia who achieved only a suboptimal response after at least 3 months of monotherapy with 400-mg imatinib. The safety of these treatments will also be evaluated.


Critère d'inclusion

  • Leukemia, Myeloid, Chronic


Liens